Schering-Plough - Biotech Market Share Report

Schering-Plough market share report graphic featuring Schering-Plough, Remicade and Peg-Intron logos. Company: Schering-Plough
2007 Sales: $2.5 billion
Market share: 3.4%
CAGR: 1.4%

What they have: Schering-Plough, which markets J&J's Remicade outside of the U.S, racked up $1.6 billion in sales in 2007. The company's pegylated interferon Hepatitis C injection Peg-Intron also brought in $911 million.

What to look for: Schering is partnered with J&J's Centocor on golimumab for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and ulcerative colitis. The company beefed up it's biotech pipeline with the $14 billion  acquisiton of Organon Biosicences last year.

Schering-Plough - Biotech Market Share Report

Suggested Articles

In a classic plot line for biotechs, Aerpio is seeking a “strategic review” for its business and assets after being hit by a trial failure.

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.